Direct-acting antiviral agents for HCV infection affecting people who inject drugs - Nature Reviews Gastroenterology & Hepatology
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Direct-acting antiviral agents for HCV infection affecting people who inject drugs - Nature Reviews Gastroenterology & Hepatology

Grebely, Jason;Hajarizadeh, Behzad;Dore, Gregory J.;Grebely, Jason;Hajarizadeh, Behzad;Dore, Gregory J.;
nature reviews gastroenterology & hepatology 2017 Vol. 14 pp. 641-651
201
jason2017naturedirect-acting

Abstract

Direct-acting antiviral agents (DAAs) are highly effective treatments for HCV, but are not always accessible to people who inject drugs (PWID). Here, Grebely and colleagues outline the epidemiology of HCV in PWID, discuss current data on DAA outcomes in this population and highlight steps required to broaden access to HCV therapy with the eventual goal of HCV elimination.

Keywords

health policy hepatitis c hepatitis c virus drug therapy

Access

DOI:
doi:10.1038/nrgastro.2017.106
URL:
http://dx.doi.org/10.1038/nrgastro.2017.106

Citation

ID: 268932
Ref Key: jason2017naturedirect-acting
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
268932
Unique Identifier:
doi:10.1038/nrgastro.2017.106
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store